Analyst Confidence: Financial firm BMO Capital initiated "Outperform" coverage on Axsome Therapeutics, citing strong drug pipeline progress and market potential. Regulatory Milestones: The U....
Analysts project Novartis (NYSE: NVS) to repo...
BMO Capital initiated an "Outperform" rating ...
Domino's Pizza (NYSE: DPZ) reported mixed second-quarter results, with earnings per share missing estimates but revenue exceeding expectations. The revenue beat was driven by strong supply ch
KeyCorp (NYSE: KEY) Earnings Preview: Regional Bank Anticipates Strong NII Growth Analysts project KeyCorp's EPS to reach $0.42, marking a 20% year-over-year increase, with total revenue expected to
Zhengye Biotechnology surged over 1047%, regaining Nasdaq compliance after a minimum bid price notice. Advanced Biomed Inc. and Axe Compute Inc. saw notable gains following a reverse stock split and
Vision Marine Technologies (NASDAQ: VEEE) experienced a sharp decline following a strategic shift from boat manufacturing to a mining project, creating investor uncertainty. Karyopharm Therapeutics I
Strong Revenue Growth Expected: Northrop Grumman is projected to report approximately $10.78 billion in revenue, a 4.1% increase year-over-year, driven by robust demand in the defense sector.
Analyst Ronald Kamdem of National Bank has set a price target of $50.00 for NNN REIT, Inc., indicating a potential upside of approximately 2.34% from its previous price of $48.86. NNN REIT, Inc. empl
